Pediatric OTC study shows caregiver confusion
This article was originally published in The Tan Sheet
Executive SummaryParents reading the front label of OTC pediatric cough/cold products overwhelmingly believe them safe for children younger than 2 years, despite language advising consultation with a doctor before administering to that age group, a study says. The report on parental misinterpretations of cough/cold drug labels, published in the June Pediatrics journal, concludes the word "infant" and graphics such as teddy bears on labels led 86 percent of the 182 recruited caregivers to say they would give the products to children younger than 2 years. After viewing an entire product package, 51 percent said they would administer the drugs to a 13-month-old, said researchers led by Russell Rothman of Vanderbilt University Medical Center. Heinz Schneider, VP of science & medical affairs for the Consumer Healthcare Products Association, noted in a May 26 statement the study created an "artificial scenario" using pediatric products that have since been withdrawn from the market in the wake of safety and efficacy concerns about pediatric cough/cold drugs (1"The Tan Sheet" Oct. 13, 2009, p. 4)
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.